Form 4 for INAB IN8BIO, INC.

Accepted 2023-12-15 00:00:00 ET · period of report 2023-12-13 · accession 0001209191-23-058716 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2023-12-15	2023-12-13	INAB	Rochlin Kate	COO	A - Grant	—	+12.3K	17.6K	+234%	—
DM	2023-12-15	2023-12-13	INAB	Rochlin Kate	COO	A - Grant	—	+24.6K	12.3K	New	—

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2023-12-13	A	A	12,295	—	17,558	D	—	—	(F1) The reported securities are included within 12,295 Issuer Units purchased by the Reporting Person for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 12,295 shares of common stock.
2	Derivative	Series B Warrants (right to buy)	2023-12-13	A	A	12,295	—	12,295	D	$1.50 · — to 2028-12-13	12,295 Common Stock	(F1) The reported securities are included within 12,295 Issuer Units purchased by the Reporting Person for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 12,295 shares of common stock. (F2) Fully vested and exercisable.
3	Derivative	Series A Warrants (right to buy)	2023-12-13	A	A	12,295	—	12,295	D	$1.25 · — to 2025-06-13	12,295 Common Stock	(F1) The reported securities are included within 12,295 Issuer Units purchased by the Reporting Person for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 12,295 shares of common stock. (F2) Fully vested and exercisable.